Salvage radiotherapy after high-intensity focused ultrasound treatment for localized prostate cancer: feasibility, tolerance and efficacy
DOI :
https://doi.org/10.5489/cuaj.18Résumé
Background: The objective of this study is to evaluate the feasibility,tolerance and efficacy of salvage external beam radiotherapy(EBRT) in persistent or recurrent prostate cancer after failed highintensity focused ultrasound (HIFU) therapy.
Methods: We reviewed data on tolerance and oncologic outcomesfor all patients with biopsy-proven locally recurrent or persistentprostate cancer who underwent salvage EBRT in our departmentbetween April 2004 and June 2008. Minimum follow-up for inclusionwas 2 years. Failure with EBRT was defined as biochemicalrelapse (Phoenix definition) or introduction of androgen deprivationtherapy (ADT). Gastrointestinal and urinary toxicity and urinary stressincontinence were scored at 12 and 24 months (Radiation TherapyOncology Group and Ingelman Sundberg rating, respectively).
Results: The mean age of the patients was 68.8 years (range: 60-79).Mean prostate-specific antigen (PSA) before EBRT was 5.57 ng/mL(range: 2.5-14.8). Median follow-up was 36.5 ± 10.9 months(range: 24-54). No patient received adjunctive ADT. The EBRTcourse was well-tolerated and completed by all patients. The meanPSA nadir was 0.62 ng/mL (range: 0.03-2.4) and occurred after amedian of 22 months (range: 12-36). One patient experiencedbiochemical failure and was prescribed ADT 30 months after EBRT.The disease-free survival rate was 83.3% at 36.5 months. Therewas no major EBRT-related toxicity at 12 or 24 months.
Conclusions: Our early clinical results confirm the feasibilityand good tolerance of salvage radiotherapy after HIFU failure.Oncological outcomes were promising. A prospective study withlonger follow-up is needed to identify factors predictive of successfor salvage EBRT therapy after HIFU failure.
Téléchargements
Références
Yancik R. Population aging and cancer: a cross-national concern. Cancer J 2005;11:437-41.
Aus G, Abbou CC, Bolla M, et al. European association of Urology. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51.
Gelet A, Chapelon JY, Bouvier R, et al. Local control of prostate cancer by transrectal High intensity focused
ultrasound therapy: preliminary results. J Urol 1999;161:156-62.
Blana A, Walter B, Rogenhofer S, et al. High intensity focused ultrasound for the treatment of localized
prostate cancer: 5-year experience. Urology 2004;63:297-300.
Blana A, Murat FJ, Walter B, et al. First analysis of the long-term result with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008;53:1194-201.
Gelet A, Chapelon JY, Bouvier R, et al. Transrectal High intensity focused ultrasound for treatment of localized prostate cancer: factors influencing the outcomes. Eur Urol 2001;40:124-9.
Challacombe BJ, Murphy DG, Zakri R, et al. High intensity focused ultrasound for localized prostate cancer: initial experience with a 2-years follow-up. BJU Int 2009;104:200-4.
Blana A, Rogenhofer S, Ganzer R, et al. Eight years’ experience with High intenstiy focused ultrasonography for treatment of localized prostate cancer. Urology 2008;72:1329-34.
Mearini l, D’Urso l, Collura D, et al. Visually directed transrectal High intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 2009 ;181:105-11; discussion 111-2.
Uchida T, Ohkusa H, Yamashita H, et al. Five years experience of transrectal high-intensity focused ultrasound
using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006;13:228-33.
Misraï V, Roupret M, Chartier-Kastler, et al. Oncologic control provided by HIFU therapy as single treatment
in men with clinically localized prostate cancer. World J Urol 2008;26:481-5.
Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
Lukka H, Waldron T, Chin J, et al. High-intensity focused ultrasound for prostate cancer: a practice guideline.
Can Urol Assoc J 2010;4:232-6.
Soulié M, Beuzeboc P, Cornud F, et al. Recommandations 2007 en onco-urologie. Prog Urol 2007;17:1157-88.
Poissonnier L, Chapelon JY, Rouvière O, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381-7.
Blana A, Murat FJ, Walter B, et al. First analysis of the long-term result with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2008;53:1194-201.
Stolzenburg JU, Bynens B, Do M, et al. Salvage laparoscopic extraperitoneal radical prostatectomy after failed High-intensity focused ultrasound and radiotherapy for localized prostate cancer. Urology 2007;70:956-60.
Liatsikos E, Bynens B, Rabenalt R, et al. Treatment of patients after failed High intensity focused ultrasound
and radiotherapy for localized prostate cancer: salvage laparoscopic extraperitoneal radical prostatectomy.
J Endourol 2008;22:2295-8.
Rebillard X, Soulié M, Chartier-Kastler E, et al. High-intensity focused ultrasound in prostate cancer: a
systematic literature review of the French Association of Urology. BJU Int 2008;101:1205-13.
Pasticier G, Chapet O, Badet L, et al. Salvage radiotherapy after high-intensity focused ultrasound for
localized prostate cancer: early clinical results. Urology 2008;72:1305-9.
Blana A, Brown SC, Chaussy C, et al. High-intensity focused ultrasound for prostate cancer : comparative
définitions of biochemical failure. BJU Int 2009;104:1058-62.
Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or
without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOGASTRO
Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
Ingelman-Sundberg A. Urinary incontinence in women. North Med 1953;50:1751-2.
Brooks JP, Albert PS, Wilder RB, et al. Long-term salvage radiotherapy outcome after radical prostatectomy
and relapse predictors. J Urol 2005;174:2204-8.
Catton C. Post-operative radiotherapy following radical prostatectomy. EAU Update Series 2005;3:107-16.
Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract
Urol 2005;2:174-82.
Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after
radical prostatectomy. JAMA 2004;291:1325-32.
Murat FJ, Poissonnier L, Rabilloud M, et al. Mid-term results demonstrate salvage High-Intensity Focused
Ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option. Eur Urol 2008;55:640-9.
Chalasani V, Martinez CH, Williams A, et al. Histological changes in the human prostate after radiotherapy
and salvage high intensity focused ultrasound. Can Urol Assoc J 2010;4:e100-2.
Blana A, Rogenhofer S, Ganzer R, et al. Morbidity associated with repeated transrectal high-intensity
focused ultrasound treatment of localized prostate cancer. World J Urol 2006;24:585-90.
Ganzer R, Rogenhofer S, Walter B, et al. PSA nadir is a significant predictor of treatment failure after
High-intensity focused ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 2008;53:547-53.
Téléchargements
Publié-e
Comment citer
Numéro
Rubrique
Licence
Les auteurs accordent les droits d’auteurs liés à l’article et son contenu à l’Association des urologues du Canada. Cette entente signifie que vous ne pouvez pas faire ce qui suit, sans d’abord obtenir l’autorisation écrite de l’AUC :
- Afficher l’article sur tout site Web.
- Traduire ou autoriser une tierce partie à traduire l’article.
- Copier ou reproduire l’article par quelque moyen que ce soit et sous tout format que ce soit, ou autoriser d’autres à le faire, au-delà de ce qui est permis par la loi canadienne du droit d’auteur.
- Copier ou reproduire des sections de l’article, y compris les tableaux et figures, par quelque moyen que ce soit, ou autoriser d’autres à le faire, au-delà de ce qui est permis par la loi canadienne du droit d’auteur.
L’AUC encourage l’usage des articles à des fins éducatives sans but commercial et ne refusera pas sans motif raisonnable toute demande d’autorisation à cet effet.
Vous conservez le droit moral lié à l’article et son contenu. Cela signifie que l’AUC ne peut utiliser ses droits d’auteurs d’une manière telle que cela pourrait avoir des répercussions négatives sur votre réputation ou sur votre droit à être associé à l’article.
L’AUC exige également que vous garantissiez ce qui suit :
- Vous êtes l’auteur ou les auteurs et seul(s) propriétaire(s) du contenu, le contenu de l’article est original et n’a jamais été publié et vous n’en avez pas déjà cédé les droits d’auteurs ni accordé de licence concernant son contenu à toute autre tierce partie;
- Toutes les personnes qui ont contribué de manière considérable à la rédaction de l’article sont mentionnées;
- L’article ne viole aucun droit de propriété de toute tierce partie, et vous avez obtenu les autorisations requises pour inclure les travaux d’autres personnes dans cet article; et
- L’article ne diffame aucune tierce partie ni ne viole les droits à la vie privée de toute tierce partie.
